152 related articles for article (PubMed ID: 27311873)
1. Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT; Tabone T; Erber W; Wood BA
Pathology; 2016 Aug; 48(5):454-62. PubMed ID: 27311873
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation in sebaceous neoplasms.
Muñoz-Jiménez MT; Blanco L; Ruano Y; Carrillo R; Santos-Briz Á; Riveiro-Falkenbach E; Requena L; Kutzner H; Garrido MC; Rodríguez-Peralto JL
Virchows Arch; 2021 Sep; 479(3):551-558. PubMed ID: 33768319
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
[TBL] [Abstract][Full Text] [Related]
4. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry.
Cabral ES; Auerbach A; Killian JK; Barrett TL; Cassarino DS
Am J Dermatopathol; 2006 Dec; 28(6):465-71. PubMed ID: 17122489
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.
Yunoki T; Hirano T; Tabuchi Y; Furusawa Y; Torigoe M; Nakajima T; Imura J; Hayashi A
Int Ophthalmol; 2020 Feb; 40(2):343-350. PubMed ID: 31571090
[TBL] [Abstract][Full Text] [Related]
6. p53 staining correlates with tumor type and location in sebaceous neoplasms.
Shalin SC; Sakharpe A; Lyle S; Lev D; Calonje E; Lazar AJ
Am J Dermatopathol; 2012 Apr; 34(2):129-35; quiz 136-8. PubMed ID: 22441365
[TBL] [Abstract][Full Text] [Related]
7. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53.
Gonzalez-Fernandez F; Kaltreider SA; Patnaik BD; Retief JD; Bao Y; Newman S; Stoler MH; Levine PA
Ophthalmology; 1998 Mar; 105(3):497-506. PubMed ID: 9499782
[TBL] [Abstract][Full Text] [Related]
8. Sebaceous carcinoma within rippled/carcinoid pattern sebaceoma.
Misago N; Toda S
J Cutan Pathol; 2016 Jan; 43(1):64-70. PubMed ID: 26268140
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
10. Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver.
Saraggi D; Salmaso R; Valentini E; Munari G; Vindigni V; Rugge M; Fassan M; Cerroni L
Pathol Res Pract; 2017 Jul; 213(7):860-862. PubMed ID: 28554764
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
12. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
13. Update on the pathology, genetics and somatic landscape of sebaceous tumours.
Ferreira I; Wiedemeyer K; Demetter P; Adams DJ; Arends MJ; Brenn T
Histopathology; 2020 Apr; 76(5):640-649. PubMed ID: 31821583
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
15. NGS Analysis Confirms Common
Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland carcinoma.
Jayaraj P; Sen S; Sharma A; Chosdol K; Kashyap S; Rai A; Pushker N; Bajaj MS; Ghose S
Br J Dermatol; 2012 Sep; 167(3):583-90. PubMed ID: 22458737
[TBL] [Abstract][Full Text] [Related]
17. Identification of potentially druggable molecular alterations in skin adnexal malignancies.
Cavalieri S; Busico A; Capone I; Conca E; Dallera E; Quattrone P; Licitra L; Pruneri G; Bossi P; Perrone F
J Dermatol; 2019 Jun; 46(6):507-514. PubMed ID: 31038235
[TBL] [Abstract][Full Text] [Related]
18. Sebaceous neoplasms: prevalence of HPV infection and relation to immunohistochemical surrogate markers.
Saliba M; Shaheen M; El Hajj R; Abbas FI; Bashir S; Sheikh UNN; Mahfouz R; Loya A; Khalifeh I
Eur J Dermatol; 2021 Apr; 31(2):170-175. PubMed ID: 34001468
[TBL] [Abstract][Full Text] [Related]
19. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
20. Sebaceous Neoplasms.
Flux K
Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
